

ACTIVASE® Vials (50 mg)Version
1.4Revision Date:
02-12-2020Date of last issue: 06-10-2017
Date of first issue: 12-05-2015**SECTION 1. IDENTIFICATION**

Product name : ACTIVASE® Vials (50 mg)

Product code : RO553-2960/F03

Common name(s), syno- : CATHFLO
nym(s) of the substance**Manufacturer or supplier's details**

Company name of supplier : Genentech, Inc.

Address : DNA Way 1
94080 South San Francisco
CA
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

Emergency telephone num- : US Chemtrec phone (800)-424-9300
ber**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance

Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with 29 CFR 1910.1200**

Not a hazardous substance or mixture.

GHS label elements

Not a hazardous substance or mixture.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Alteplase	105857-23-6	2.14
Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs.	9005-65-6	0.21
L-Arginine	74-79-3	
Phosphoric acid	7664-38-2	

ACTIVASE® Vials (50 mg)Version
1.4Revision Date:
02-12-2020Date of last issue: 06-10-2017
Date of first issue: 12-05-2015**SECTION 4. FIRST AID MEASURES**

- General advice : Do not leave the victim unattended.
- If inhaled : Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.
- In case of skin contact : If on skin, rinse well with water.
- In case of eye contact : Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.
- If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Rinse mouth with water.
- Most important symptoms and effects, both acute and delayed : None known.
- Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Specific hazards during fire fighting : No information available.
- Hazardous combustion products : In case of fire hazardous decomposition products may be produced such as:
Phosphorus compounds
Carbon monoxide
Nitrogen oxides (NO_x)
Sulfur oxides
- Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protection : Avoid dust formation.

ACTIVASE® Vials (50 mg)

Version
1.4

Revision Date:
02-12-2020

Date of last issue: 06-10-2017
Date of first issue: 12-05-2015

tive equipment and emergency procedures

Environmental precautions : Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion : Provide appropriate exhaust ventilation at places where dust is formed.

Advice on safe handling : For personal protection see section 8. Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions : See label, package insert or internal guidelines

Materials to avoid : No materials to be especially mentioned.

Storage temperature : 2 °C to 8 °C
Protected from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: glass, glass bottles

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Phosphoric acid	7664-38-2	TWA	1 mg/m ³	ACGIH
		STEL	3 mg/m ³	ACGIH
		TWA	1 mg/m ³	NIOSH REL
		ST	3 mg/m ³	NIOSH REL
		TWA	1 mg/m ³	OSHA Z-1
		TWA	1 mg/m ³	OSHA P0
		STEL	3 mg/m ³	OSHA P0
Alteplase	105857-23-6	IOEL	0.2 mg/m ³	Roche Industrial Hygiene Committee (RIHC)

ACTIVASE® Vials (50 mg)Version
1.4Revision Date:
02-12-2020Date of last issue: 06-10-2017
Date of first issue: 12-05-2015**Engineering measures** : No data available**Personal protective equipment**

Respiratory protection : No personal respiratory protective equipment normally required.

Hand protection

Material : Protective gloves

Remarks : Wear appropriate protective gloves to prevent skin contact.
Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : solid, (lyophilized)

Color : white, off-white

Odor : Not applicable

Odor Threshold : Not applicable

Melting point/range : No data available

Boiling point/boiling range : No data available

Flash point : does not flash

Self-ignition : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : Not applicable

Relative density : No data available

Solubility(ies)

Water solubility : No data available

ACTIVASE® Vials (50 mg)

Version 1.4 Revision Date: 02-12-2020 Date of last issue: 06-10-2017
Date of first issue: 12-05-2015

Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

 Viscosity, dynamic : Not applicable

 Viscosity, kinematic : Not applicable

Metal corrosion rate : Not corrosive to metals.

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Stable under recommended storage conditions.
No hazards to be specially mentioned.

Incompatible materials : No data available

Hazardous decomposition products : No data available

SECTION 11. TOXICOLOGICAL INFORMATION**Acute toxicity**

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:**L-Arginine:**

Acute oral toxicity : LD50 Oral (Rat): > 5,110 mg/kg

Phosphoric acid:

Acute oral toxicity : LD50 (Rat): 1,530 mg/kg
LD50 (Mouse): 1,250 mg/kg

Acute inhalation toxicity : LC50 (Rat): 850 mg/m³

ACTIVASE® Vials (50 mg)

Version
1.4

Revision Date:
02-12-2020

Date of last issue: 06-10-2017
Date of first issue: 12-05-2015

Exposure time: 1 h
Test atmosphere: vapor

LC50 (Mouse): 25,5 mg/m³
Test atmosphere: vapor

Acute dermal toxicity : LD50 (Rabbit): 2,740 mg/kg

Alteplase:

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration) : TDLo (Rat): > 10 mg/kg
Application Route: i.v.

Skin corrosion/irritation

Not classified based on available information.

Product:

Result : No skin irritation
Remarks : Expert judgment

Components:

L-Arginine:

Remarks : May cause skin irritation in susceptible persons.

Phosphoric acid:

Remarks : Extremely corrosive and destructive to tissue.

Serious eye damage/eye irritation

Not classified based on available information.

Product:

Result : No eye irritation
Remarks : Expert judgment

Components:

L-Arginine:

Result : Irritating to eyes.
Remarks : May cause irreversible eye damage.

Phosphoric acid:

Result : Risk of serious damage to eyes.

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

ACTIVASE® Vials (50 mg)

Version
1.4

Revision Date:
02-12-2020

Date of last issue: 06-10-2017
Date of first issue: 12-05-2015

Respiratory sensitization

Not classified based on available information.

Product:

Assessment : No eye irritation, No skin irritation

Germ cell mutagenicity

Not classified based on available information.

Components:

Alteplase:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Test system: mammalian cells
Result: negative

Test Type: Ames test
Result: negative

Carcinogenicity

Not classified based on available information.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

STOT-single exposure

Not classified based on available information.

Components:

L-Arginine:

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure

Not classified based on available information.

Components:

L-Arginine:

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Repeated dose toxicity

Product:

ACTIVASE® Vials (50 mg)Version
1.4Revision Date:
02-12-2020Date of last issue: 06-10-2017
Date of first issue: 12-05-2015Repeated dose toxicity -
Assessment : No eye irritation, No skin irritation**Components:****Alteplase:**Species : Several species
LD0 : 10 mg/kg
Application Route : i.v.
Exposure time : 14 d**Aspiration toxicity**

Not classified based on available information.

Components:**L-Arginine:**

No data available

Further information**Components:****Alteplase:**

Remarks : anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described with other monoclonal antibodies

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****L-Arginine:**Toxicity to fish : LC50 (Brachydanio rerio (zebrafish)): 2,800 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
GLP: yesNOEC (Brachydanio rerio (zebrafish)): 1,000 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
GLP: yesToxicity to daphnia and other
aquatic invertebrates : NOEC (Daphnia magna (Water flea)): 1,000 mg/l
Exposure time: 24 h
Method: OECD Test Guideline 202
GLP: yesToxicity to microorganisms : EC10 (Pseudomonas putida): < 10,000 mg/l
Exposure time: 16 h
Method: DIN 38 412 Part 8
GLP: yes

ACTIVASE® Vials (50 mg)Version
1.4Revision Date:
02-12-2020Date of last issue: 06-10-2017
Date of first issue: 12-05-2015**Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to
the environment : No data available**Phosphoric acid:**

Toxicity to fish : LC50 (Fish): 70 mg/l

Toxicity to daphnia and other
aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5,000 mg/l
Exposure time: 24 h
Method: OECD Test Guideline 202Toxicity to algae/aquatic
plants : EC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201NOEC (Desmodesmus subspicatus (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201**Ecotoxicology Assessment**

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to
the environment : No data available**Persistence and degradability****Components:****Alteplase:**

Biodegradability : Result: Globular proteins are generally well biodegradable

Bioaccumulative potential**Components:****L-Arginine:**Partition coefficient: n-
octanol/water : log Pow: -4.2**Phosphoric acid:**Partition coefficient: n-
octanol/water : Remarks: No data available**Alteplase:**

ACTIVASE® Vials (50 mg)
Version
1.4Revision Date:
02-12-2020Date of last issue: 06-10-2017
Date of first issue: 12-05-2015

Partition coefficient: n-octanol/water : Remarks: No data available

Mobility in soil

No data available

Other adverse effects**Product:**

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Components:**L-Arginine:**

Adsorbed organic bound halogens (AOX) : Remarks: Not applicable

Additional ecological information : No data available

Alteplase:

Additional ecological information : Protein with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

SECTION 13. DISPOSAL CONSIDERATIONS
Disposal methods

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION
International Regulations**UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

ACTIVASE® Vials (50 mg)

Version 1.4 Revision Date: 02-12-2020 Date of last issue: 06-10-2017
 Date of first issue: 12-05-2015

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation

49 CFR

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

Components	CAS-No.	Component RQ (lbs)	Calculated product RQ (lbs)
Phosphoric acid	7664-38-2	5000	*

*: Calculated RQ exceeds reasonably attainable upper limit.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

Components	CAS-No.	Component TPQ (lbs)

SARA 311/312 Hazards : No SARA Hazards

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Table 116.4A:

Phosphoric acid 7664-38-2 >= 20 - < 30 %

The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 117.3:

Phosphoric acid 7664-38-2 >= 20 - < 30 %

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

US State Regulations

Massachusetts Right To Know

Phosphoric acid 7664-38-2

Pennsylvania Right To Know

L-Arginine 74-79-3

Phosphoric acid 7664-38-2

ACTIVASE® Vials (50 mg)

Version
1.4

Revision Date:
02-12-2020

Date of last issue: 06-10-2017
Date of first issue: 12-05-2015

Maine Chemicals of High Concern

Vermont Chemicals of High Concern

Washington Chemicals of High Concern

California List of Hazardous Substances

Phosphoric acid 7664-38-2

California Permissible Exposure Limits for Chemical Contaminants

Phosphoric acid 7664-38-2

The ingredients of this product are reported in the following inventories:

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Alteplase

AICS : Not in compliance with the inventory

NZIoC : Not in compliance with the inventory

ENCS : Not in compliance with the inventory

ISHL : Not in compliance with the inventory

KECI : Not in compliance with the inventory

PICCS : Not in compliance with the inventory

IECSC : Not in compliance with the inventory

TCSI : Not in compliance with the inventory


TSCA : Substance(s) not listed on TSCA inventory

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION

ACTIVASE® Vials (50 mg)Version
1.4Revision Date:
02-12-2020Date of last issue: 06-10-2017
Date of first issue: 12-05-2015**NFPA:****HMIS® IV:**

HEALTH	/	0
FLAMMABILITY		0
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA P0	:	USA. OSHA - TABLE Z-1 Limits for Air Contaminants - 1910.1000
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
ACGIH / STEL	:	Short-term exposure limit
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
NIOSH REL / ST	:	STEL - 15-minute TWA exposure that should not be exceeded at any time during a workday
OSHA P0 / TWA	:	8-hour time weighted average
OSHA P0 / STEL	:	Short-term exposure limit
OSHA Z-1 / TWA	:	8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of

ACTIVASE® Vials (50 mg)

Version
1.4

Revision Date:
02-12-2020

Date of last issue: 06-10-2017
Date of first issue: 12-05-2015

Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 02-12-2020

The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 1810